Bioniq

Bioniq is a precision health platform that brings individualized medical optimization — the kind historically available only to professional athletes, elite sports programs, and high-net-worth health enthusiasts with access to private sports medicine clinics — to a broader consumer audience. The service centers on blood biomarker analysis, using that biological data as the foundation for a personalized supplement formulation that is revised and updated every three months based on each user's most recent test results, creating a continuous loop of measurement, personalization, and re-evaluation. The company was founded in London in 2019 by Vadim Fedotov, a former professional basketball player whose career gave him direct experience of what rigorous, data-driven health optimization looks like in practice. During his athletic career, Fedotov had access to blood-based health analysis and personalized nutritional protocols that most people — even those aware that such approaches exist — cannot access affordably. His founding thesis was that the scientific principles underlying elite performance health management could be translated into a consumer product accessible to health-conscious individuals outside professional sports. Bioniq's initial commercial focus targeted high performers — entrepreneurs, executives, endurance athletes, and professional operators for whom optimizing cognitive and physical function was a genuine priority and who were already comfortable with the concept of data-driven health management. From that early adopter base, the platform has progressively expanded toward mainstream consumers interested in preventive health, positioning itself in the commercially significant territory between mass-market supplements sold at every pharmacy and the expensive, physician-supervised longevity medicine programs available at private clinics. The pricing and accessibility of Bioniq's service bring meaningful precision health within reach of a consumer segment that has grown substantially as biomarker-based wellness has moved from fringe interest to mainstream health media conversation. The platform's core differentiator is the iterative scientific rigor of its approach. Every three-month testing cycle produces new data that updates the supplement formulation, and the results of that updated protocol are measured in the subsequent cycle. This ongoing feedback loop — powered by a proprietary and growing dataset linking biomarker profiles to supplementation interventions — becomes progressively more precise with each iteration. The individual user benefits from an increasingly accurate personalization; the platform benefits from a dataset that generic supplement companies have no mechanism to collect or leverage. In a market being reshaped by the convergence of affordable diagnostics, consumer wearables, and artificial intelligence, Bioniq's combination of blood science, algorithmic personalization, and subscription-based iterative refinement has established a distinctive position between mass-market supplement retail and expensive clinical precision medicine.